Myosin in autoinhibited off state(s), stabilized by mavacamten, can be recruited via inotropic effectors

Mavacamten is a novel, FDA-approved, small molecule therapeutic designed to regulate cardiac function by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin towards ordered off states close to the thick filament backbone. It remains unresolved whether mavacamten...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Weikang, del Rio, Carlos L., Qi, Lin, Prodanovic, Momcilo, Mijailovich, Srboljub, Zambataro, Christopher, Gong, Henry, Shimkunas, Rafael, Gollapudi, Sampath, Nag, Suman, Irving, Thomas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120679/
https://www.ncbi.nlm.nih.gov/pubmed/37090664
http://dx.doi.org/10.1101/2023.04.10.536292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120679/
https://www.ncbi.nlm.nih.gov/pubmed/37090664
http://dx.doi.org/10.1101/2023.04.10.536292

Ejemplares similares